Presentation is loading. Please wait.

Presentation is loading. Please wait.

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Published byZsuzsanna Balog Modified over 5 years ago

Similar presentations

Presentation on theme: "Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant."— Presentation transcript:

1 Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer  Ho Yun Lee, MD, Hyun Ju Lee, MD, Young Tae Kim, MD, Chang Hyun Kang, MD, Bo Gun Jang, MD, Doo Hyun Chung, MD, Jin Mo Goo, MD, Chang Min Park, MD, Chang Hyun Lee, MD, Keon Wook Kang, MD  Journal of Thoracic Oncology  Volume 5, Issue 4, Pages (April 2010) DOI: /JTO.0b013e3181d2efe7 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Time to recurrence (TTR) based on tumor response on computed tomography (CT). Comparing patients with and without radiologic responses (≥30% reduction of tumor size), there was no significant difference in the TTR between the two groups (mean TTR, 44.7 versus 24.5 months and median TTR, not reached versus 16.8 months, respectively; p = 0.11). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Time to recurrence (TTR) based on tumor response by positron emission tomography/computed tomography (PET/CT, ≥25% reduction of SUVmax). Comparing patients with and without responses, there was no significant difference in the TTR between the two groups (mean TTR, 42.1 versus 23.9 months and median TTR, not reached versus 18.2 months, respectively; p = 0.19). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Time to recurrence (TTR) based on tumor response by positron emission tomography/computed tomography (PET/CT, ≥50% reduction of SUVmax). Patients with a metabolic response of ≥50% reduction of SUVmax had a longer TTR than patients without response (mean TTR, 51.7 versus 22.7 months and median TTR, not reached versus 18.2 months, respectively; p = 0.005). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Time to recurrence (TTR) based on radiologic-metabolic tumor response (≥30% reduction of tumor size and ≥25% reduction of SUVmax). Radiologic-metabolic responders had a longer TTR than patients with radiologic-metabolic nonresponse, radiologic response only, and metabolic response only (mean TTR, 49.4 versus 23.5 months and median TTR not reached versus 16.8 months, respectively; p = 0.022). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Time to recurrence (TTR) based on radiologic-metabolic tumor response (≥30% reduction of tumor size as well as ≥50% reduction of SUVmax). Radiologic-metabolic responders had a longer TTR than patients with radiologic-metabolic nonresponse, radiologic response only, and metabolic response only (mean TTR, 58.7 months versus 22.3 months and median TTR, not reached versus 16.8 months, respectively; p = 0.001). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Time to recurrence (TTR) based on pathologic response. Patients with a pathologic response of ≤10% of viable tumor cells had a longer TTR than patients without response (mean TTR, 44.2 months versus 31.7 months and median TTR, not reached versus 23.1 months, respectively; p = 0.015). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant."

Similar presentations

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.
A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Quantification of emphysema with preoperative computed tomography has stronger association with pulmonary complications than pulmonary function test results.

Quantification of emphysema with preoperative computed tomography has stronger association with pulmonary complications than pulmonary function test results.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.
Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful.

Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis  Hyun Lee, MD,

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis  Hyun Lee, MD,
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Similar presentations

Ads by Google